In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Investors buy out ReNeuron Holdings

Executive Summary

The Merlin Consortium is buying Europe's first publicly traded stem cell firm ReNeuron Holdings PLC (therapeutics for neurological disorders) for £3.6mm ($5.7mm), or about 181 times its 2002 revenues. St. James's will delist ReNeuron from the London AIM (taking it to the private sector) and rename it ReNeuron Ltd.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Buy-out
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies